| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetrics Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology - Clinical Trials Consortium (CKD-EPI CT) | Heerspink, H.J., Eddington, D., Chaudhari, J., Estacio, R., Imai, E., Goicoechea, M., Hannedouche, T., Haynes, R., Jafar, T.H., Johnson, D.W. and van Kruijsdijk, R.C., 2024. A meta-analysis of randomized controlled clinical trials implications of acute treatment effects on glomerular filtration rate for long-term kidney protection. Kidney International. Doi: 10.1016/j.kint.2024.05.024 | GlaxoSmithKline, Takeda | 4 | |
| 4915 | Rachel Tomko | Medical University of South Carolina | Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy | Wolf, B.J., Gray, K.M., Dahne, J.R., Hashemi, D. and Tomko, R.L., 2024. Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial. Nicotine and Tobacco Research, p.ntae290. Doi: 10.1093/ntr/ntae290 | Pfizer | 0 | |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Takase-Minegishi, K., Böhringer, S., Nam, J.L., Kaneko, Y., Behrens, F., Saevarsdottir, S., Detert, J., Leirisalo-Repo, M., van der Heijde, D., Landewé, R. and Ramiro, S., 2024. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology, p.keae113. DoI: 10.1093/rheumatology/keae113 | AbbVie, Pfizer | 2 | |
| 4926 | Eva-Maria Gamper | Medical University Innsbruck | Comparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its use | Pilz, M.J., Seyringer, S., Al-Naesan, I., King, M.T., Bottomley, A., Norman, R., Schlosser, L., Hell, T. and Gamper, E.M., 2024. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients' Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs. PharmacoEconomics-Open, pp.1-14. Doi: 10.1007/s41669-024-00484-9 | Boehringer Ingelheim | 3 | |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V., Ravindranath, V., Arneson, D., Mosenia, A., Butte, A. and Wang, S., 2023. S936 Optimizing Treatment Selection in Crohn's Disease Using Patient-Specific Features: An Individual Participant Data Meta-Analysis of Fifteen Randomized Controlled Trials. Official journal of the American College of Gastroenterology| ACG, 118(10S), pp.S701-S702. Doi: 10.1016/S0016-5085(24)03735-1 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | N/A | |
| 5435 | Matthew Gilbert | University of Vermont | Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled Trial | Gilbert, M.P., Skelly, J., Hernandez, A.F., Green, J.B., Krychtiuk, K.A., Granger, C.B., Leiter, L.A., McMurray, J.J., Del Prato, S. and Pratley, R.E., 2024. Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism. Doi: 10.1111/dom.15479 | GlaxoSmithKline | 0 | |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | J. Wilk, V. Aggarwal, M. Pauley, D. Corey, D. Conrado, K. Lingineni, J. Morales, D. Yoon, J. Burton, J. Larkindale, S. Ma, C. Hovinga, T. Martinez, K. Romero, R. Belfiore-Oshan, S. Kim. A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES. American Society for Clinical Pharmacology & Therapeutics. [See Browse by Poster Title tab]. Poster PII-179. 2024. | CureDuchenne | N/A | N/A |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Wilk, J., Aggarwal, V., Pauley, M., Corey, D., Conrado, D.J., Lingineni, K., Morales, J.F., Yoon, D.Y., Zhang, Y., Cui, Z. and Burton, J., A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies. CPT: Pharmacometrics & Systems Pharmacology. Doi: 10.1002/psp4.13281 | CureDuchenne | N/A | 0 |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Lees, J., Crowther, J., Hanlon, P., Butterly, E.W., Wild, S.H., Mair, F., Guthrie, B., Gillies, K., Dias, S., Welton, N.J. and Katikireddi, S.V., 2024. Participant characteristics and exclusion from phase 3/4 industry funded trials of chronic medical conditions: meta-analysis of individual participant level data. BMJ medicine, 3(1). Doi: 10.1136/bmjmed-2023-000732 | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB | 0 | |
| 5921 | Paul Schulz | University of Texas Health Science Center | Identification of biomarkers associated with Alzheimer's disease progression that correlate with responses to medications | Wang, D., Ma, X., Schulz, P.E., Jiang, X. and Kim, Y., 2024. Clinical outcome-guided deep temporal clustering for disease progression subtyping. Journal of Biomedical Informatics, 158, p.104732. Doi: 10.1016/j.jbi.2024.104732 | Lilly | 1 | |
| 5921 | Paul Schulz | University of Texas Health Science Center Houston | Identification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications. | Wang, D, Ling, Y, Harris, K, Schulz, P, Jiang, X and Kim, Y. Characterizing Treatment Non-responders and Responders in Completed Alzheimer's Disease Clinical Trials. American Medical Informatics Association (AMIA) Presentation S110, 2024. Presentation link | Lilly | N/A | N/A |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Duarte, C., Ferreira, R.J., Welsing, P.M., Jacobs, J.W., Gossec, L., Machado, P.M., van der Heijde, D. and da Silva, J.A.P., 2024. Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?. RMD open, 10(1), p.e003972. Doi: 10.1136/rmdopen-2023-003972 | AbbVie, Pfizer, Roche, UCB | 1 | |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Duarte, C., Jacobs, J.W., Ferreira, R.J., Welsing, P.M., Gossec, L., Machado, P.M., van der Heijde, D. and da Silva, J.A.P., 2024. Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data. RMD open, 10(4), p.e004387. Doi: 10.1136/rmdopen-2024-004387 | AbbVie, Pfizer, Roche, UCB | 1 | |
| 5989 | Alexandre Betourne | Critical Path Institute | Sharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes | Betourne, A., Romero, K., Ma, S., &, Zhang, Y. Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach. 2024. American Conference on Pharmacometrics. Poster M-079. | AbbVie | N/A | N/A |
| 6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Dubbelman, M.A., Vromen, E.M., Tijms, B.M., Berkhof, J., Ottenhoff, L., Vijverberg, E.G., Prins, N.D., van der Flier, W.M. and Sikkes, S.A., 2024. Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(3), p.e12485. https://doi.org/10.1002/trc2.12485 | Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly | 1 | |
| 6471 | Vincent Lanting | University of Amsterdam Academic Medical Center | Risk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysis | Lanting, V., Takada, T., Bosch, F., Marshall, A., Grosso, M., Young, A., Lee, A.Y., Di Nisio, M., Raskob, G., Kamphuisen, P.W. and Buller, H.R., Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thrombosis and haemostasis. DOI: 10.1055/a-2418-3960 | Pfizer | 0 | |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Krotka, P., Posch, M., Gewily, M., Höglinger, G. and Roig, M.B., 2024. Statistical modeling to adjust for time trends in adaptive platform trials utilizing non-concurrent controls. arXiv preprint arXiv:2403.14348. Doi: 10.48550/arXiv.2403.14348 | AbbVie | N/A | |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Gewily, M., Plan, E.L., Yousefi, E., König, F., Posch, M., Hopfner, F., Hölinger, G. and Karlsson, M.O., 2024. Quantitative comparisons of progressive supranuclear palsy rating scale versions using item response theory. Movement Disorders. Doi: 10.1002/mds.30001 | AbbVie | 2 | |
| 6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | Ahuja, D., Luo, J., Qi, Y., Syal, G., Boland, B.S., Chang, J., Ma, C., Jairath, V., Xu, R. and Singh, S., 2024. Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn's Disease: Secondary Analysis of the PYRAMID Registry. Clinical Gastroenterology and Hepatology. Doi: 10.1016/j.cgh.2024.01.003 | AbbVie | 2 | |
| 6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | Ahuja, D., Luo, J., Qi, Y., Syal, G., Boland, B., Chang, J., Ma, C., Jairath, V., Xu, R. and Singh, S., 2024. IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN'S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY. Inflammatory Bowel Diseases, S1(30), p.S1. Doi: 10.1093/ibd/izae020.001 | AbbVie | N/A | |
| 6758 | Qian Chen | Hubei Cancer Hospital | Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy | Chen, Q., Yuan, S., Liu, N., Wang, H., Shang, X., Ma, X., Sun, Y., Wei, C., Liu, L., Wang, X. and Liu, Y. Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis. JCO 42, 20570. (2024). Doi:10.1200/JCO.2024.42.16_suppl.e20570 | Roche | N/A | N/A |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Ding, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Wang, G., Tang, J., Cao, J. and He, L., 2024. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial. Breast Cancer Research, 26(1), pp.1-10. Doi: 10.1186/s13058-023-01761-x | Roche | 5 | |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Pang, J., Ding, N., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Li, Y., He, Y., Wang, S. and Xiao, Z., 2024. Prognostic value of the baseline systemic immune-inflammation index in HER2-positive metastatic breast cancer: exploratory analysis of two prospective trials. Annals of Surgical Oncology, pp.1-10. Doi: 10.1245/s10434-024-16454-8 | Roche | 5 | |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, J.G., Yang, J., Wang, H., Wong, A.H.H., Tan, F., Chen, X., Shen, G., Wang, Y.J., Frey, B., Fietkau, R. and Hecht, M., Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy. Doi: 10.1136/bmjonc-2023-000128 | Bristol Myers Squibb, Project Data Sphere, Roche | 1 | |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Xu, J., Wang, H., Zhang, C., Jin, S.H., Chen, X., Tan, F., Frey, B., Hecht, M., Sun, J.G., Gaipl, U.S. and Ma, H., 2024. Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC. iScience. Doi: 10.1016/j.isci.2024.111363 | Bristol Myers Squibb, Project Data Sphere, Roche | 0 | |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | J. Shen, J. Ma, S. Chen, Q. Li, S. Jin, C. Zhang, H. Wang, X. Chen, F. Tan, X. Tian, H. Zhang, G. Pan, U. Gaipl, H. Ma, J. Zhou. Quality of life scale-based machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer. 2024. Annals of Oncology (2024) 35 (suppl_2): S1197-S1204. Doi: 10.1016/annonc/annonc1586 | Bristol Myers Squibb, Project Data Sphere, Roche | N/A | N/A |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, J.G., Xu, J., Wang, H., Zhang, C., Jin, S.H., Chen, X., Tan, F., Frey, B., Hecht, M., Gaipl, U.S. and Ma, H., 2024. Efficacy of Radiotherapy Combined with Atezolizumab or Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer: A PSM-IPTW Cohort Study. International Journal of Radiation Oncology, Biology, Physics, 120(2), pp.e89-e90. Doi: 10.1016/j.ijrobp.2024.07.1979 | Bristol Myers Squibb, Project Data Sphere, Roche | N/A | |
| 6860 | Nicholas Lange | Columbia University | Belatacept in obese kidney transplant recipients | Lange, N.W., King, K., Husain, S.A., Salerno, D.M., Tsapepas, D.S., Hedvat, J., Yu, M. and Mohan, S., 2024. Obesity is associated with a higher incidence of rejection in patients on belatacept: a pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials. American Journal of Transplantation. Doi: 10.1016/j.ajt.2024.02.015 | Bristol Myers Squibb | 1 | |
| 6866 | Andy Lim | Monash University | Meta-analysis of early stroke recurrence rate in minor stroke | Lim, A., Ma, H., Johnston, S.C., Singhal, S., Muthusamy, S., Wang, Y., Pan, Y., Coutts, S.B., Hill, M.D., Ois, A. and Kapral, M.K., 2023. Ninetyâ€Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta-Analysis of Trials and Observational Studies. Journal of the American Heart Association, p.e032471. Doi: 10.1161/JAHA.123.032471 | AstraZeneca | 8 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica, B., Romiti, G.F., Proietti, M., Mei, D.A., Boriani, G., Ding, W.Y., Olshansky, B., Huisman, M.V. and Lip, G.Y.H., 2024. Early rhythm control in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III. Europace, 26(Supplement_1), pp.euae102-066. Doi: 10.1093/europace/euae102.066 | Boehringer Ingelheim | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Lam, S.H.M., Romiti, G.F., Olshansky, B., Chao, T.F., Huisman, M.V. and Lip, G.Y.H., 2024. Combination therapy of beta-blockers and digoxin is associated with increased risk of major adverse cardiovascular events and all-cause mortality in patients with atrial fibrillation: a report from the GLORIA-AF registry. Internal and Emergency Medicine, pp.1-10. Doi: 10.1007/s11739-024-03629-0 | Boehringer Ingelheim | 1 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Ishiguchi, H., Abdul-Rahim, A.H., Huang, B. et al. Residual Risks of Thrombotic Complications in Anticoagulated Patients with Atrial Fibrillation: A Cluster Analysis Approach from the GLORIA-AF Registry. J GEN INTERN MED (2024). Doi: 10.1007/s11606-024-09045-6 | Boehringer Ingelheim | 1 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Liu, Y., Chen, Y., Lam, S.H., Huang, B., Romiti, G.F., Alam, U., Chao, T.F., Olshansky, B., Hong, K., Huisman, M.V. and Lip, G.Y., 2024. Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA-AF registry phase III. Diabetes, Obesity and Metabolism, 26(12), pp.5795-5804. Doi: 10.1111/dom.15950 | Boehringer Ingelheim | 2 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Li, M., Huang, B., Lam, S.H.M., Ishiguchi, H., Liu, Y., Olshansky, B., Huisman, M.V., Chao, T.F. and Lip, G.Y., 2024. Long-term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer: A report from the GLORIAâ€AF registry. European Journal of Clinical Investigation, p.e14347. Doi: 10.1111/eci.14347 | Boehringer Ingelheim | 0 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Huang, B., Lam, H.M., Ishiguchi, H., Liu, Y., Chao, T.F., Olshansky, B., Huisman, M. and Lip, G., 2024. Temporal trends and regional differences of initial oral antiarrhythmic drug options in patients with new-onset atrial fibrillation: a report from the GLORIA-AF registry. European Heart Journal, 45(Supplement_1), pp.ehae666-3319. Doi: 10.1093/eurheartj/ehae666.3319 | Boehringer Ingelheim | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Huang, B.I., Li, M., Liu, Y., Lam, H.M., Ishiguchi, H., Chao, T.F., Olshansky, B., Huisman, M. and Lip, G., 2024. Incidence, characteristics, and prognostic impact of cancers in patients with atrial fibrillation: a report from the GLORIA-AF registry. European Heart Journal, 45(Supplement_1), pp.ehae666-3154. Doi: 10.1093/eurheartj/ehae666.3154 | Boehringer Ingelheim | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Liu, Y., Chen, Y., Lam, S.H.M., Huang, B., Chao, T.F., Olshansky, B., Huisman, M. and Lip, G.Y.H., 2024. Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: implications of insulin treatment: a report from the GLORIA-AF Registry Phase III. European Heart Journal, 45(Supplement_1), pp.ehae666-463. Doi: 10.1093/eurheartj/ehae666.463 | Boehringer Ingelheim | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Liu, Y., Chen, Y., Lam, S.H.M., Huang, B., Chao, T.F., Olshansky, B. and Lip, G.Y.H., 2024. Implications of renal function on adverse clinical events in patients with atrial fibrillation: a comparative analysis of VKA and NOAC therapy-Insights from the GLORIA-AF Registry Phase III. European Heart Journal, 45(Supplement_1), pp.ehae666-603. Doi: 10.1093/eurheartj/ehae666.603 | Boehringer Ingelheim | N/A | |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | Gunter, S.J., Holcomb, Z.E., Lam, B.D., Porter, M.L. and Kimball, A.B., 2024. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab. JAMA dermatology. Doi: 10.1001/jamadermatol.2024.1075 | AbbVie | 0 | |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | Gunter, S.J., Porter, M.L. and Kimball, A.B., 2024. Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials. International Journal of Women's Dermatology, 10(3), p.e171. Doi: 10.1097/JW9.0000000000000171 | AbbVie | 0 | |
| 7142 | Sara Tedeschi | Brigham and Women's Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Tedeschi, S.K., Hayashi, K., Zhang, Y., Choi, H. and Solomon, D.H., 2024. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. Annals of the Rheumatic Diseases. Doi: 10.1136/ard-2024-225761 | Takeda | 2 | |
| 7156 | Angelina Tjokrowidjaja | University of Sydney | Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis | Tjokrowidjaja, A., Friedlander, M.L., Ledermann, J.A., Coleman, R.L., Mirza, M.R., Matulonis, U.A., Pujade-Lauraine, E., Lord, S.J., Scott, C.L., Goble, S. and York, W., 2024. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly (ADP-ribose) Polymerase Inhibitor. Journal of Clinical Oncology, JCO-23. Doi: 10.1200/JCO.23.01182 | AstraZeneca | 7 | |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | Kerr, W.T., Kok, N., Reddy, A.S., McFarlane, K.N., Stern, J.M., Pennell, P.B., Stacey, W. and French, J., 2024. Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications. Neurology, 103(4), p.e209713. Doi: 10.1212/WNL.0000000000209713 | GlaxoSmithKline, Johnson & Johnson, UCB | 1 | |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | Auclin, E., Dugage, M.R., Gorria, T., Vauchier, C., Thibault, C., Laguna, J.C., Lupinacci, L., Crous, C., Naigeon, M., Oudard, S., Mezquita, L.,Besse, B., 2025. Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials. Lung Cancer, 199, p.108039. Doi: 10.1016/j.lungcan.2024.108039 | Project Data Sphere, Roche | 1 | |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Chhibba, T., Wong, E.C., Reinisch, W., Targownik, L. and Narula, N., 2024. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. European Journal of Gastroenterology & Hepatology, 36(6), pp.704-711. Doi: 10.1097/MEG.0000000000002759 | Takeda | 1 | |
| 7288 | Vipual Jairath | Alimentiv Inc. | Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials | Solitano, Virginia, Hogan, Malcolm, Singh, Siddharth, Danese, Silvio, Peyrin-Biroulet, Laurent, Zou, Guangyong, Yuan, Yuhong, Sands, Bruce E., Feagan, Brian G., Dulai, Parambir S., Narula, Neeraj, Ma, Christopher and Jairath, Vipul "Placebo Rates in Crohn’s Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis". Gastroenterology vol. 168, no. 2, Feb. 2025, pp. 344-356. https://doi.org/10.1053/j.gastro.2024.10.009 | AbbVie, Johnson & Johnson, Takeda | N/A | 3 |
| 7288 | Vipual Jairath | Alimentiv Inc. | Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials | Solitano, V, Hogan, M, Singh, S, Danese, S, Peyrin-Biroulet, L, Zayadi, A, Zou, G, Sands, B E, Feagan, B G, Narula, N, Ma, C and Jairath, V. P1013 Placebo rates in Crohn's disease: An individual patient data meta-analysis from multiple randomised controlled trials. Journal of Crohn's and Colitisvol. 18, no. Supplement_1, Jan. 2024, pp. i1821-i1823. https://doi.org/10.1093/ecco-jcc/jjad212.1143 | AbbVie, Johnson & Johnson, Takeda | N/A | N/A |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Guo, T., Zhou, Y., Liang, F., Wang, Z., Bourbonne, V., Käsmann, L., Sundahl, N., Wu, A.J.C., Ni, J. and Zhu, Z., 2024. Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials. Translational Lung Cancer Research, 13(1), p.126. Doi: 10.21037/tlcr-23-792 | Roche | 3 | |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Zhou, Y., Guo, T., Liang, F., Wang, Z., Zhang, J., Ni, J. and Zhu, Z., 2024. Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150. Cancer. Doi: 10.1002/cncr.35242 | Roche | 0 | |
| 7384 | Ulrich Mansmann | Ludwig-Maximilian’s University München | Application of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials | Al Tawil, A., McGrath, S., Ristl, R. and Mansmann, U., 2024. Addressing treatment switching bias in the ALTA-1L trial with g-methods: exploring the impact of model specification. BMC Medical Research Methodology. Doi: 10.1186/s12874-024-02437-6 | AstraZeneca, Roche, Takeda | 0 | |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients Takeda | Ghang, B. Delayed progression of chronic kidney disease in gout patients during urate-lowering therapy: A patient-level post-hoc analysis of the CARES trial. International Journal of Rheumatic Diseases, 27 (Suppl. 2) P013. Doi: 10.1111/1756-185X.15172 | Takeda | N/A | N/A |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients Takeda | Ghang, B., Park, J., Lee, J.S., Lim, J.S., Kim, H., Liew, D.F., Kim, J., Kang, D.H. and Yoo, B., 2024. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney International. Doi: 10.1016/j.kint.2024.10.022 | Takeda | 3 | |
| 7400 | Aryelly Rodriguez | The University of Edinburgh | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | Rodriguez, A., Williams, L.J., Lewis, S.C., Sinclair, P., Eldridge, S., Jackson, T., and Weir, C.J. Using re-identification risk scores on publicly available anonymised clinical trial datasets. ICTMC 2024. Abstract PS.8B-3. 2024. | GlaxoSmithKline, UCB | N/A | N/A |
| 7493 | Nina Hilkens | Radboudumc Nijmegen | Blood pressure variability and progression of white matter hyperintensities after ischemic strokes | Hilkens, N.A., de Leeuw, F.E., Klijn, C.J. and Richard, E., 2024. Blood pressure variability and white matter hyperintensities after ischemic stroke. Cerebral Circulation-Cognition and Behavior, p.100205. Doi: 10.1016/j.cccb.2024.100205 | Boehringer Ingelheim | 3 | |
| 7549 | Vipul Jairath | Alimentiv Inc | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | Solitano, V., Panaccione, R., Sands, B.E., Wang, Z., Zou, G., Peyrin-Biroulet, L., Danese, S., Cornfield, L.J., Feagan, B.G., Singh, S. and Jairath, V., 2024. P280 Comparative responsiveness of disease activity indices in moderately-to-severely active Ulcerative Colitis: a post-hoc analysis of the UNIFI trial. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i647-i648. Doi: 1093/ecco-jcc/jjad212.0410 | AbbVie, Johnson & Johnson, Takeda | N/A | |
| 7549 | Vipul Jairath | Alimentiv Inc | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | V. Solitano, R. Panaccione, B. E. Sands, S. Singh, V. Jairath, C. Ma. Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis. 2024. Preprint. Med. Doi: 10.1016/j.medj.2024.09.001 | AbbVie, Johnson & Johnson, Takeda | 0 | |
| 7587 | Yashmin Karten | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran S., Karten Y., Cullen N., Lau C., Priest E., White H., Irizarry M. DE-RISKING CLINICAL TRIAL DESIGN VIA MODEL-INFORMED DRUG DEVELOPMENT WITH THE CRITICAL PATH FOR ALZHEIMER'S DISEASE CONSORTIUM. Alzheimer's & Parkinson's Diseases Conference. Abstract Shift 2-0149. 2024. | Lilly | N/A | N/A |
| 7587 | Yashmin Karten | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran, S., Priest, E., Lau, C., Irizarry, M.C. and Karten, Y., 2024, July. Critical Path for Alzheimer's Disease (CPAD) Consortium: Data-Driven Solutions for Clinical Trial Design and Informed Decision Making. In Alzheimer's Association International Conference. ALZ. | Lilly | N/A | N/A |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment | Parent N, Hopkins AM, Sorich MJ. Machine learning for enhanced survival prediction from tumour growth inhibition data. Population Approach Group of Australia and New Zealand (PAGANZ). Oral Presentation. 2024. | Roche | N/A | N/A |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment | Li LX, Hopkins AM, Sorich MJ. Methodologically appropriate evaluation of continuous BMI as a clinical predictor of chemoimmunotherapy efficacy in advanced non-small cell lung cancer. Population Approach Group of Australia and New Zealand (PAGANZ). Oral Presentation. 2024. | Roche | N/A | N/A |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic outcomes to immune checkpoint inhibitors used in cancer treatment_012022 | Li, L.X., Socinski, M.A., Kichenadasse, G., Karapetis, C.S., Shahnam, A., McKinnon, R.A., Rowland, A., Hopkins, A.M. and Sorich, M.J., 2024. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials. BMC cancer, 24(1), p.379. | Roche | 0 | |
| 7598 | Harry Southworth | Data Clarity Consulting Ltd | Exploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data mining | Southworth H., Schubiner H. Statistical investigation of comorbidities of back pain in the medical history data from clinical trials of healthy subjects. 2024. Open Science Framework (OSF). Doi: 10.17605/OSF.IO/APXUT | AstraZeneca, GlaxoSmithKline | N/A | |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Wang, Q. and Hong, H., 2024. Bayesian hierarchical models with calibrated mixtures of g-priors for assessing treatment effect moderation in meta-analysis. arXiv preprint arXiv:2410.24194. Doi: 10.48550/arXiv.2410.24194 | Johnson & Johnson, Lundbeck, Takeda | N/A | |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Di Stefano, L.S., 2024. Taming Interactions in Genomics and Clinical Trials (Doctoral dissertation, Johns Hopkins University). | Johnson & Johnson, Lundbeck, Takeda | N/A | N/A |
| 7601 | Guru Sonpavde | AdventHealth Cancer Institute | Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitors | Graser, C., McDonald, T.O., Sonpavde, G. and Michor, F., 2024. Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab. Cancer Research, 84(6_Supplement), pp.2392-2392. Doi: 10.1158/1538-7445.AM2024-2392 | Roche | N/A | |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Salter, A., Lancia, S., Fitzgerald, K., Ann Marrie, R., 2024. Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations. Neurology. 102(5). doi: 10.1212/WNL.0000000000209135 | Roche | 9 | |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Salter, A., Lancia, S., Kowalec, K., Fitzgerald, K.C. and Marrie, R.A., Comorbidity and Disease Activity in Multiple Sclerosis. JAMA neurology. Doi: 10.1001/jamaneurol.2024.2920 | Roche | 10 | |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Salter, A., Lancia, S., Fitzgerald, K., Kowalec, K., Marrie, R. A. The Association of Comorbidities and Disease Activity in Phase III Clinical Trials for Disease-Modifying Therapies in Multiple Sclerosis. ECTRIMS 2024. Multiple Sclerosis Journal. 2024;30(3_suppl):4-124. Doi: 10.1177/13524585241269218 | Roche | N/A | |
| 7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | Narula, N., Hamam, H., Wong, E.C., Marshall, J.K., Jairath, V., Hanauer, S.B., Reinisch, W. and Dulai, P.S., 2024. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials. Journal of Crohn's and Colitis, 18 (Supplement_1), pp.i1308-i1308. Doi: 10.1093/ecco-jcc/jjad212.0819 | AbbVie, Johnson & Johnson, Pfizer, Takeda | N/A | |
| 7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | Narula, N., Hamam, H., Liu, J., Wong, E.C., Marshall, J.K., Jairath, V., Hanauer, S.B., Reinisch, W. and Dulai, P.S., 2024. Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in clinical trials of ulcerative colitis. Journal of Crohn's and Colitis, p.jjae092. Doi: 10.1093/ecco-jcc/jjae092 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 4 | |
| 7662 | Benoit You | Université Claude Bernard Lyon | Prognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) | A. Carrot, A., Oudard, S., Fizazi, K., Maillet, D., Sartor, O., Freyer, G., You, B. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO Clin Cancer Inform 8, e2300208(2024). DOI :10.1200/CCI.23.00208 | Sanofi | 2 | |
| 7663, 7385 | Amit Etkin | Alto Neuroscience, Inc. | Cognitive predictors of antidepressant treatment outcome in patients with major depressive disorder | Jordan, J.T., Shen, L., Cooper, N.J., Goncalves, S.V., Trivedi, M.H., Schatzberg, A.F., Wu, W., Savitz, A.J. and Etkin, A., 2024. Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled Trials. The Journal of Clinical Psychiatry, 85(4), p.56760. Doi: 10.4088/JCP.24m15295 | Lilly, Lundbeck, Takeda | 0 | |
| 7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis | Tadount, F., Kiely, M., Assi, A., Rafferty, E., Sadarangani, M., MacDonald, S.E. and Quach, C., 2024, April. Sex Differences in the Immunogenicity and Efficacy of Seasonal Influenza Vaccines: A Meta-analysis of Randomized-Controlled Trials. In Open Forum Infectious Diseases (p. ofae222). Oxford University Press. Doi: 10.1093/ofid/ofae222 | Sanofi | 7 | |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Matos, A., Henriques, C., Doria, A. and Inês, L.S., 2024. P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials. Doi: 10.1136/lupus-2024-el.181 | AstraZeneca | N/A | |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L.S., 2024. P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials. Doi: 10.1136/lupus-2024-el.121 | AstraZeneca | N/A | |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L.S., 2024. O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials. Doi: 10.1136/lupus-2024-el.31 | AstraZeneca | N/A | |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L., 2024. POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS. Annals of the Rheumatic Diseases, 83, pp.1004-1005. | AstraZeneca | N/A | N/A |
| 7797 | Jörg Ellinger | University Hospital Bonn | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Brossart, P., Ellinger, J., Hölzel, M. and Klümper, N., 2024. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition. Lung Cancer, 189, p.107505. https://doi.org/10.1016/j.lungcan.2024.107505 | Pfizer, Project Data Sphere, Roche | 8 | |
| 7811 | Gustavo Turecki | McGill University | Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder | Mehltretter, J., Fratila, R., Perlman, K., Tunteng, J.-F., Popescu, C., Turecki, G., & Benrimoh, D. (2024). Using Artificial Intelligence to Personalize Initial Treatment Selection in Bipolar Depression. Zenodo. Doi: 10.5281/zenodo.12747378 | AbbVie, Lilly, Otsuka, Takeda | N/A | N/A |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | Xu, Y., Mallity, C., Collins, E., Siegal, D.M., Wang, T.F. and Carrier, M., 2024. Anticoagulation for the Prevention of Arterial Thromboembolism in Cancer Patients by Primary Tumor Site: A Systematic Review and Meta-Analysis of Randomized Trials. European Heart Journal-Cardiovascular Pharmacotherapy, p.pvae068. Doi: 10.1093/ehjcvp/pvae068 | GlaxoSmithKline, Sanofi | 1 | |
| 7828 | Ramiro Sofia | Leiden University Medical Center | SPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | Benavent, D., Navarro-Compán, V., Capelusnik, D. and Ramiro, S., 2024. POS0799 EFFICACY OF BDMARDS IN EARLY VERSUS ESTABLISHED DISEASE IN AXIAL SPONDYLOARTHRITIS: A META-ANALYSIS OF RANDOMIZED TRIALS. Doi: 10.1136/annrheumdis-2024-eular.2352 | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB | N/A | |
| 7844 | Linong Ji | Peking University People's Hospital | Risk stratification and responder identification for glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Type 2 Diabetes Mellitus (T2DM): a machine learning facilitated post-hoc analysis of clinical trials | HUANG, Q., ZOU, X., BOYKO, E.J. and JI, L., 2024. 925-P: Using Machine Learning to Predict Dynamic Cardiovascular Risks and Identify the Treatment Responses of Canagliflozin in Type 2 Diabetes Mellitus. Diabetes, 73 (Supplement_1). Doi: 10.2337/db24-925-P | BioLINCC, GlaxoSmithKline, Johnson & Johnson | N/A | |
| 7845 | Craig Nelson | University of California San Francisco | Change in cognition during antidepressant treatment of late life depression | "A Systematic Review of Antidepressants and Psychotherapy Commonly Used in the Treatment of Late Life Depression for Their Effects on Cognition". The American Journal of Geriatric Psychiatryvol. 33, no. 3, Mar. 2025, pp. 287-304 | Lilly, Lundbeck | 0 | |
| 7848 | Jennifer Lund | University of North Carolina at Chapel Hill | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Lund, J.L., Webster-Clark, M.A., Westreich, D., Sanoff, H.K., Robert, N., Frytak, J.R., Boyd, M., Shmuel, S., Stürmer, T. and Keil, A.P., 2024. Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice. Epidemiology, 35(2), pp.241-251. Doi: 10.1097/EDE.0000000000001694 | Sanofi | 2 | |
| 7850 | Vipul Jairath | University of Western Ontario | Impact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel Disease | Ahuja, D., Zou, G., Solitano, V., Syal, G., Lee, H.H., Ma, C., Jairath, V. and Singh, S., 2024. No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis. Clinical Gastroenterology and Hepatology. Doi: 10.1016/j.cgh.2024.08.040 | AbbVie, Johnson & Johnson, Pfizer, Takeda, UCB | 1 | |
| 7854 | Vipul Jairath | University of Western Ontario | Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials | Vuyyuru, S.K., Ma, C., Nguyen, T.M., Zou, G., Peyrin-Biroulet, L., Danese, S., Dulai, P., Narula, N., Singh, S. and Jairath, V., 2024. Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials. eClinicalMedicine, 72. Doi: 10.1016/j.eclinm.2024.102621 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 1 | |
| 7856 | Evandro de Azambuja | Institut Jules Bordet | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Debien, V., Agostinetto, E., Bruzzone, M., Ceppi, M., Martins-Branco, D., Molinelli, C., Jacobs, F., Nader-Marta, G., Lambertini, M. and de Azambuja, E., 2024. The impact of initial tumor response on survival outcomes of patients with HER2-positive advanced breast cancer treated with docetaxel, trastuzumab, and pertuzumab: an exploratory analysis of the CLEOPATRA trial. Clinical Breast Cancer. Doi: 10.1016/j.clbc.2024.02.012 | Roche | 5 | |
| 7858 | Jie Zha | Xiamen University | Retrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patients | Zha, J., Chen, Q., Zhang, W., Jing, H., Ye, J., Liu, H., Yu, H., Yi, S., Li, C., Zheng, Z. and Xu, W., 2025. A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma. Biomarker Research, 13(1), p.2. Doi: 10.1186/s40364-024-00716-4 | Roche | 1 | |
| 7868 | Anne-Marie Dingemans | Erasmus MC University Medical Center | Predictive clinical characteristics for weight gain in patients treated with alectinib | Sikkema, B.J., Baart, S.J., Paats, M.S., Smit, E.F., Schols, A.M., Mathijssen, R.H., van Rossum, E.F. and Dingemans, A.M.C., 2024. Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials. Journal of Clinical Oncology, pp.JCO-24. Doi: 10.1200/JCO-24-01579 | Roche | 3 | |
| 8052 | Wataru Fukuokaya | The Jikei University School of Medicine | Association of serum magnesium levels with effectiveness of atezolizumab in advanced urothelial carcinoma | Fukuokaya, W., Akazawa, K. and Kimura, T., 2024. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma. Anticancer Research, 44(5), pp.2117-2123. Doi: 10.21873/anticanres.17017 | Roche | 0 | |
| 8180 | Sheng Luo | Duke University | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer | Li, H., Wu, Y., Zou, H., Koner, S., Plichta, J.K., Tolaney, S.M., Zhang, J., He, Y.W., Wei, Q., Tang, L. and Zhang, H., 2024. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. EBioMedicine, 105. Doi: 10.1016/j.ebiom.2024.105186 | Daiichi Sankyo, Lilly, Pfizer, Roche | 10 | |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Doyle, F. Byrne, D., Boland F. 2024. Do psychometrics matter? The effects of psychometrics on depression trial outcomes. International Meeting of the Psychomtric Society. Abstract. pg.377 | GlaxoSmithKline, Lilly, Pfizer, Takeda | N/A | N/A |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Doyle F., Byrne D., Boland F. Do psychometrics 'matter'? Mixed methods study of applying advanced psychometrics in depression treatment trials. Annual Conference of the European Health Psychology Society. 2024. Pg. 639. | GlaxoSmithKline, Lilly, Pfizer, Takeda | N/A | N/A |
| 8266 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | The prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis | Zheng, J., Zheng, D., Fan, Z., Li, L., Chen, R. and Zhang, S., 2024. Developing and Externally Validating a Simple Index Based on the Nonlinear Relationship of Fecal Calprotectin and Long-Term Outcomes in Ulcerative Colitis. Journal of Inflammation Research, pp.11247-11256. Doi: 10.2147/JIR.S497655 | Takeda | 0 | |
| 8344 | Xiaoling Shang | Shandong University | A clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide | Zhang, C., Huo, Y., Shang, X., Zhang, T., Tang, N. and Wang, H., 2024. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer. Respiratory Research, 25(1), p.253. | Roche | 1 | |
| 8344 | Xiaoling Shang | Shandong University | A clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide | Shang, X., Zhang, C., Lv, Y., Zhang, X., Guo, K., Li, H. and Wang, H., 2024. Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment. ImmunoTargets and Therapy, pp.571-583. Doi: 10.2147/ITT.S483093 | Roche | 2 | |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Almansour, S.A., Alqudah, M.A., Abuhelwa, Z., Al-Shamsi, H.O., Alhuraiji, A., Semreen, M.H., Bustanji, Y., Alzoubi, K.H., Modi, N.D., Mckinnon, R.A. and Sorich, M.J., 2024. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Therapeutic Advances in Medical Oncology, 16, p.17588359241275387. Doi: 10.1177/17588359241275387 | Johnson & Johnson, Sanofi, Takeda | 0 | |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Almansour, S.A., Alqudah, M.A., Abuhelwa, Z., Al-Shamsi, H.O., Semreen, M.H., Bustanji, Y., Soare, N.C., McKinnon, R.A., Sorich, M.J., Hopkins, A.M. and Abuhelwa, A.Y., 2024. Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials. Scientific Reports, 14(1), p.591. Doi: 10.1038/s41598-023-48640-1 | Johnson & Johnson, Sanofi, Takeda | 2 | |
| 8438 | Sheng Luo | Duke University | Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time | Zhou, X., Zou, H., Lutz, M.W., Arbeev, K., Akushevich, I., Yashin, A., Welsh-Bohmer, K.A. and Luo, S., 2024. Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(2), p.e12471. Doi: 10.1002/trc2.12471 | AbbVie | 1 | |
| 8440 | David Seiffge | Insel Gruppe AG | Andexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC | Siepen, B.M., Polymeris, A., Shoamanesh, A., Connolly, S., Steiner, T., Poli, S., Lemmens, R., Goeldlin, M.B., Müller, M., Branca, M. and Rauch, J., 2023. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors—Individual patient data analysis of ANNEXA-4 and TICH-NOAC. International Journal of Stroke, p.17474930 241230209. Doi: 10.1177/17474930241230209 | AstraZeneca | 7 | |
| 8450 | Dennis McGonagle | University of Leeds | The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients | David, P., Hen, O., Ben-Shabbat, N., Macleod, T., Amital, H., Watad, A. and McGonagle, D.G., 2024. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects. RMD open, 10(2), p.e004045. Doi: 10.1136/rmdopen-2023-004045 | Lilly | 0 | |
| 8558 | Pablo Guisado Vasco | Hospital Universitario Quironsalud Madrid; Universidad Europea (Madrid) | Investigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patients | Aguareles , J., Forné , C., García-Casas , A. , Carnevali-Ruiz , D., Sotres-Fernández , G., Solera Rallo , J.T. and Guisado-Vasco , P. "Influence of anti-spike protein antibody levels on tocilizumab efficacy in hospitalised patients with severe COVID-19 pneumonia: a post hoc analysis of the COVACTA trial". CMI Communications pp.387-388, 2024 doi:https://doi.org/10.1016/j.cmicom.2024.100013 | Roche | N/A | N/A |
| 8559 | Dag Aarsland | King's College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Xue, L., Bocharova, M., Young, A.H. and Aarsland, D., 2024. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms. Journal of affective disorders. Doi: 10.1016/j.jad.2024.06.003 | Lundbeck | 3 | |
| 8560 | Emily Fox | Stanford University | Hybrid machine learning modeling of Insulin-Glucose dynamics for T1D | Zou, B, Levine, M, Zaharieva, D, Johari, R and Fox, E. "Neural ODE Causal Modeling and an Application to Glycemic Response". arXiv 2024 | Jaeb Center for Health Research Foundation, Inc. | N/A | |
| 8561 | Dale Morrison | The University of Melbourne | IMPROVING EXERCISE WITH TYPE 1 DIABETES | Morrison, D., Vogrin, S. and Zaharieva, D.P., 2024. Assessment of Glycemia Risk Index and Standard Continuous Glucose Monitoring Metrics in a Real-World Setting of Exercise in Adults With Type 1 Diabetes: A Post-Hoc Analysis of the Type 1 Diabetes and Exercise Initiative. Doi: 10.1177/19322968241246458 | Jaeb Center for Health Research Foundation, Inc. | 1 | |
| 8582 | David Cherne | University Health Network | Modelling Studies to Assess Sodium-Glucose co-Transporter-2 (SGLT2) Inhibition Effects and Kidney Protection in Type 1 Diabetes | Nardone, M., Kugathasan, L., Sridhar, V., Dutta, P., Campbell, D., Layton, A.T., Perkins, B.A., Barbour, S., Lam, T.K., Levin, A. and Lovblom, L.E., 2024. Modeling Cardiorenal Protection with SGLT2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and-2: FR-PO312. Journal of the American Society of Nephrology, 35(10S), pp.10-1681. Doi: 10.1681/ASN.2024s5r4rxwp | AstraZeneca, Boehringer Ingelheim | N/A | N/A |
| 8582 | David Cherne | University Health Network | Modelling Studies to Assess Sodium-Glucose co-Transporter-2 (SGLT2) Inhibition Effects and Kidney Protection in Type 1 Diabetes | Kugathasan, L., Dutta, P., Nardone, M., Sridhar, V., Campbell, D., Layton, A.T., Perkins, B.A., Barbour, S., Lam, T.K., Levin, A. and Lovblom, L.E., 2024. Modeling Cardiorenal Protection with SGLT2 Inhibition in Type 1 Diabetes: An Analysis of EASE-2 and-3: TH-OR53. Journal of the American Society of Nephrology, 35(10S), pp.10-1681. Doi: 10.1681/ASN.2024w22c75k8 | AstraZeneca, Boehringer Ingelheim | N/A | N/A |
| 8602 | Robert Hamilton | University of Toronto | Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial | Chavarriaga, J., Lajkosz, K., Sangole, N., Penn, L.Z., Khurram, N. and Hamilton, R.J., 2024, October. Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial. In Urologic Oncology: Seminars and Original Investigations. Elsevier. Doi: 10.1016/j.urolonc.2024.08.023 | Bayer | 0 | |
| 8603 | Wencai Jiang | Chengdu Second People's Hospital | Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease | Jiang, W., Huang, G., Du, J., Yang, H., Zhou, S., Dai, D., Tang, K., Fang, Y., Wang, X. and Deng, X., 2024. White blood cell counts can predict 4-year cardiovascular disease risk in patients with stable coronary heart disease: a prospective cohort study. Frontiers in Cardiovascular Medicine, 11, p.1358378. Doi: 10.3389/fcvm.2024.1358378 | GlaxoSmithKline | 2 | |
| 8609 | Fredrik Schjesvold | Oslo University Hospital | Personalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. | Myklebust, E.M., Schjesvold, F., Frigessi, A., Leder, K., Foo, J. and Köhn-Luque, A., 2024. Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone. medRxiv, pp.2024-05. Doi: 10.1101/2024.05.02.24306607 | Sanofi | N/A | N/A |
| 8611 | Adam de Havenon | Yale University | Baseline Stroke Severity in Secondary Prevention Trials | de Havenon, A., Viscoli, C., Kleindorfer, D., Sucharew, H., Delic, A., Becker, C., Robinson, D., Yaghi, S., Li, V., Lansberg, M.G. and Cramer, S.C., 2024. Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials. JAMA Network Open, 7(7), pp.e2423677-e2423677. Doi: 10.1001/jamanetworkopen.2024.23677 | Boehringer Ingelheim | 1 | |
| 8686 | Andrea E. van der Meulen - de Jong | Leiden University Medical Center | Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis | Loveikyte, R., Voorneveld, P.W., Dijkstra, G. and van der Meulen-de Jong, A.E., 2024. P923 Haematological abnormalities during treatment with Janus kinase inhibitors in patients with Ulcerative Colitis: a post hoc analysis. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i1681-i1681. Doi: 10.1093/ecco-jcc/jjad212.1053 | Pfizer | N/A | |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Klümper, N., Cox, A., Eckstein, M., Kuppe, C., Ritter, M., Brossart, P., Luetkens, J., Hölzel, M., Stein, J. and Saal, J., 2024. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. European Journal of Cancer, p.114089. Doi: 10.1016/j.ejca.2024.114089 | Roche | 2 | |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Eckstein, M., Ritter, M., Brossart, P., Luetkens, J., Ellinger, J., Grünwald, V., Hölzel, M. and Klümper, N., 2024. Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy. JAMA oncology. Doi: 10.1001/jamaoncol.2024.5672 | Roche | 1 | |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Eckstein, M., Ritter, M., Brossart, P., Hölzel, M., Grünwald, V. and Klümper, N., 2025. The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. European Journal of Cancer, 215, p.115163. Doi: 10.1016/j.ejca.2024.115163 | Roche | 2 | |
| 8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Alfehaid, L.S., Farah, S., Omer, A., Weber, B.N., Alkhezi, O., Tawfik, Y.M., Shah, A.M., Libby, P. and Buckley, L.F., 2024. Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19: A Secondary Analysis of the COLCORONA Randomized Clinical Trial. JAMA Network Open, 7(9), pp.e2431309-e2431309. Doi: 10.1001/jamanetworkopen.2024.31309 | Montreal Heart Institute | 3 | |
| 8747 | Arsalan Shahid | CeADAR: Ireland's Centre for Applied AI at University College Dublin | Unlocking the Secrets of Glucose Variability: A Machine Learning and Data-Driven Analysis of Hypoglycemia and Hyperglycemia | Riddell, Michael C., Lewis, Dana M., Turner, Lauren V., Lal, Rayhan A., Shahid, Arsalan and Zaharieva, Dessi P. "Refining Insulin on Board with netIOB for Automated Insulin Delivery". Journal of Diabetes Science and Technologyvol. , no. , Aug. 2024. https://doi.org/10.1177/19322968241267820 | Jaeb Center for Health Research Foundation, Inc. | 1 | |
| 8747 | Arsalan Shahid | CeADAR: Ireland's Centre for Applied AI at University College Dublin | Unlocking the Secrets of Glucose Variability: A Machine Learning and Data-Driven Analysis of Hypoglycemia and Hyperglycemia | Shahid, Arsalan and Lewis, Dana M. "Impact of Hypoglycemia on Glucose Variability over Time for Individuals with Open-Source Automated Insulin Delivery Systems". Diabetology vol. 5, no. 5, Oct. 2024, pp. 514-536. https://doi.org/10.3390/diabetology5050038 | Jaeb Center for Health Research Foundation, Inc. | N/A | |
| 8764 | Giuseppe Cabibbo | University of Palermo | Competing risk factors in survival analyses for advanced hepatocellular carcinoma outcomes. The key role of liver function and impact of drug class | Cabibbo, G., Celsa, C., Battaglia, S., Enea, M., Di Maria, G., Grova, A., Ciccia, R., Manfredi, G.F., Iavarone, M., Vogel, A. and Singal, A.G., 2024. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Clinical Cancer Research. Doi: 10.1158/1078-0432.CCR-24-2582 | Roche | 2 | |
| 8766 | Catherine Russon | University of Exeter | Using machine learning methods to predict the risk of exercise-induced hypoglycemia in people with Type 1 diabetes | Russon, C.L., Allen, M.J., Pulsford, R.M., Saunby, M., Vaughan, N., Cocks, M., Hesketh, K.L., Low, J. and Andrews, R.C., 2024. A User-Friendly Web Tool for Custom Analysis of Continuous Glucose Monitoring Data. Journal of Diabetes Science and Technology, 18(6), pp.1511-1513. Doi: 10.1177/19322968241274322 | Jaeb Center for Health Research Foundation, Inc. | 0 | 2 |
| 8837 | Erin Tallon | Children's Mercy Kansas City | Development of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 Diabetes | Panfil K, Tallon EM, Lockee B, Williams DD, Patton SR, Clements M. Impact of moderate-to-vigorous physical activity on continuous glucose monitor-derived metrics in youth with type 1 diabetes. Diabetes Technol Ther 2024; 26(S2):EV257. Doi: 10.1089/dia.2024.2525.abstracts | Jaeb Center for Health Research Foundation, Inc. | N/A | |
| 8845 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Biomarkers for predicting long-term outcomes in ulcerative colitis | Zheng, J., Zhang, X., Zhang, L., Li, L., Chen, M., Chen, R. and Zhang, S., 2024. Serum Albumin and Its Trajectory Are Associated with Therapeutic Outcomes in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. Doi: 10.1016/j.cgh.2024.10.036 | AbbVie, Johnson & Johnson, Takeda | 0 | |
| 8879 | Micaela Morettini | Università Poiltecnica delle Marche | Development of a decision support solution to prevent hypoglycemia during and after exercise in T1D | Piersanti, A., Del Giudice, L.L., Göbl, C., Burattini, L., Tura, A. and Morettini, M., 2024. Role of pre-exercise CGM metrics on hypoglycemic events in young patients with type 1 diabetes. IL DIABETE | Jaeb Center for Health Research Foundation, Inc. | N/A | N/A |
| 8926 | Alessio Cortellini | Imperial College London | The putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials. | Cortellini A., Santo V., Brunetti L., Mangani D., Anderson A.C., Vincenzi B., Tonini G., Takada K., Naqash A.R., Ricciuti B., Pinato D.J. Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials. JCO 42, 2607-2607(2024). Doi: 10.1200/JCO.2024.42.16_suppl.2607 | Roche | N/A | |
| 8933 | Joao Pedro Ferreira | University of Porto | Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozin | Ferreira, J.P., Zannad, F., Packer, M., Filippatos, G., Pocock, S.J., Vasques-Nóvoa, F., Böhm, M., Butler, J. and Anker, S., 2024. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis. European Journal of Heart Failure. Doi: 10.1002/ejhf.3180 | Boehringer Ingelheim | 2 | |
| 8957 | Dean Bodenham | Imperial College London | Two-sample testing for clinical trials data with missing values | Zeng Y., Adams N.M., Bodenham D.A. 2024. On two-sample testing for data with arbitrarily missing values. arXiv preprint. Doi: 10.48550/arXiv.2403.15327 | Bayer | N/A | |
| 9103 | JOSE GARCIA-TIRADO | University of Bern | Automatic Recognition of Main Glycemic Disturbances in Type 1 Diabetes (T1D) | CYPRIS, L.E. and GARCIA-TIRADO, J.F., 2024. 243-OR: Characterization of Behavioral Patterns Involving Hypoglycemic Episodes in Type 1 Diabetes—Results from the T1DEXI Study Cohort. Diabetes, 73(Supplement_1). Doi : 10.2337/db24-243-OR | Jaeb Center for Health Research Foundation, Inc. | N/A | N/A |
| 9137 | Ly-Mee Yu | University of Oxford | Loop Diuretics and Weight Change in Heart Failure A Meta-Analysis | Phan, Y., 2024. Meta-Analysis on Aggregate Data and Individual Patient Data Using R. Phuse EU Connect. Abstract PP06. | Bayer, Boehringer Ingelheim, GlaxoSmithKline | N/A | N/A |
| 9241 | Amit Garg | Northwell Health | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | Midgette, B., Strunk, A. and Garg, A., 2024. Association between skin-related quality of life and race in patients with moderate-to-severe hidradenitis suppurativa: Analysis of two phase 3 clinical trials. Journal of the American Academy of Dermatology. Doi: 10.1016/j.jaad.2024.07.1508 | AbbVie | 0 | |
| 9241 | Amit Garg | Northwell Health | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | Midgette B, Strunk A, Garg A. Association Between Skin-Related Quality of Life and Race in Patients with Hidradenitis Suppurativa. Annual Meeting of the Medical Dermatology Society. Poster. 2024. | AbbVie | N/A | N/A |
| 9244 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Impact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy A Post Hoc Analysis of IMpower133 | Takada, K., Takamori, S., Shimokawa, M., Pinato, D.J. and Cortellini, A., Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial. International journal of cancer. Doi: 10.1002/ijc.35249 | Roche | 3 | |
| 9286 | Joao Sergio Neves | Faculdade de Medicina da Universidade do Porto | Effect of Exenatide Across the Spectrum of Ejection Fraction: An analysis from the EXSCEL trial | Neves, J.S., Leite, A.R., Mentz, R.J., Holman, R.R., Zannad, F., Butler, J., Packer, M. and Ferreira, J.P., 2024. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial. European Journal of Heart Failure. Doi: 10.1002/ejhf.3478 | AstraZeneca | 6 | |
| 9332 | Neeraj Narula | Hamilton Health Sciences | Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease | Samnani, S., Wong, E.C., Hamam, H., Dulai, P.S., Marshall, J.K., Jairath, V., Reinisch, W. and Narula, N., 2024. Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease. Journal of Crohn's and Colitis, p.jjae151. Doi: 10.1093/ecco-jcc/jjae151 | Johnson & Johnson, Takeda | 2 | |
| 9383 | Joao Pedro Ferreira | Faculty of Medicine of Porto University | Anemia and the Effect of Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF) findings from EMPEROR-Preserved | Ferreira, J.P., Zannad, F., Vasques-Nóvoa, F., Neves, J.S., Filippatos, G., Pocock, S.J., Butler, J., Packer, M. and Anker, S.D., 2024. Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Heart Journal, p.ehae864. Doi: 10.1093/eurheartj/ehae864 | Boehringer Ingelheim | 0 | |
| 9492, 8697 | David McAllister | University of Glasgow | Understanding frailty, multimorbidity and renal failure in clinical trials Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions | Hanlon, P., Butterly, E., Wei, L., Wightman, H., Almazam, S.A.M., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K. and Lewsey, J., 2024. Age-and sex-differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data. medRxiv, pp.2024-06. Doi: 10.1101/2024.06.23.24309242 | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB | N/A | N/A |
| 10039, 8807 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Liu H., Ray T., Friberg LE. Comparison between multistate and parametric time-to-event models for analysis of progression-free-survival (PFS) and overall survival (OS) in oncology trials. 2024. Population Approach Group People, PAGE 32. Abstract 10980. | Pfizer | N/A | N/A |
| 10118 | Neeraj Narula | Hamilton Health Sciences | Assessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD) | Wong, E.C., Dulai, P.S., Marshall, J.K., Laroux, S., Jairath, V., Reinisch, W. and Narula, N., 2024. Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial. Journal of Crohn's and Colitis, p.jjae171. Doi: 10.1093/ecco-jcc/jjae171 | AbbVie | 0 |
Center for Global Research Data